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Abstract
Background: Uterine serpins are members of the serine proteinase inhibitor superfamily. Like
some other serpins, these proteins do not appear to be functional proteinase inhibitors. The most
studied member of the group, ovine uterine serpin (OvUS), inhibits proliferation of several cell
types including activated lymphocytes, bovine preimplantation embryos, and cell lines for
lymphoma, canine primary osteosarcoma and human prostate cancer (PC-3) cells. The goal for the
present study was to evaluate the mechanism by which OvUS inhibits cell proliferation. In
particular, it was tested whether inhibition of DNA synthesis in PC-3 cells involves cytotoxic
actions of OvUS or the induction of apoptosis. The effect of OvUS in the production of the
autocrine and angiogenic cytokine interleukin (IL)-8 by PC-3 cells was also determined. Finally, it
was tested whether OvUS blocks specific steps in the cell cycle using both PC-3 cells and
lymphocytes.
Results: Recombinant OvUS blocked proliferation of PC-3 cells at concentrations as low as 8 μg/
ml as determined by measurements of [ 3H]thymidine incorporation or ATP content per well.
Treatment of PC-3 cells with OvUS did not cause cytotoxicity or apoptosis or alter interleukin-8
secretion into medium. Results from flow cytometry experiments showed that OvUS blocked the
entry of PC-3 cells into S phase and the exit from G2/M phase. In addition, OvUS blocked entry of
lymphocytes into S phase following activation of proliferation with phytohemagglutinin.
Conclusion: Results indicate that OvUS acts to block cell proliferation through disruption of the
cell cycle dynamics rather than induction of cytotoxicity or apoptosis. The finding that OvUS can
regulate cell proliferation makes this one of only a few serpins that function to inhibit cell growth.
Background
Serine proteinase inhibitors (serpins) inactivate their tar-
get proteinases through a suicide substrate-like inhibitory
mechanism. The proteinase binds covalently to the reac-
tive center loop (RCL) of the serpin and cleaves the scissile
bond at the P1-P1' site. The RCL then moves to the oppo-
site side to form the β-sheet A and a distortion in the struc-
ture of the proteinase that results in its inactivation [1-3].
Not all serpins, however, exert proteinase inhibitory activ-
ity. Some examples are corticosteroid and thyroxine bind-
ing globulins, which function as hormone transport
proteins [4], the chaperone heat shock protein 47 [5],
mammary serine protease inhibitor (Maspin), which
increases the sensitivity of cancer cells to undergo apopto-
sis [6], and pigment epithelium derived factor (PEDF),
Published: 24 January 2008
BMC Cell Biology 2008, 9:5 doi:10.1186/1471-2121-9-5
Received: 17 August 2007
Accepted: 24 January 2008
This article is available from: http://www.biomedcentral.com/1471-2121/9/5
© 2008 Padua and Hansen; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cell Biology 2008, 9:5 http://www.biomedcentral.com/1471-2121/9/5
Page 2 of 10
(page number not for citation purposes)
which has neurotrophic, neuroprotective, antiangiogenic,
and proapoptotic actions [7].
Another class of serpins without apparent proteinase
activity is the uterine serpins. These proteins, which are
produced by the endometrial epithelium of the pregnant
cow, sow, sheep, and goat [8-13], have been classified as
either a separate clade of the serpin superfamily [14] or as
a highly-diverge group of the α1-antitrypsin clade [1]. The
best characterized protein of this unique group of serpins
is ovine uterine serpin (OvUS). This basic glycoprotein is
a weak inhibitor of aspartic proteinases (pepsin A and C)
[12,15], but it does not inhibit a broad range of serine
proteinases [9,16]. Additionally, amino acids in the hinge
region of inhibitory serpins are not conserved in uterine
serpins and OvUS behaves different in the presence of
guanidine HCl than for inhibitory serpins [13,15].
The biological function of OvUS during pregnancy may
be to inhibit immune cell proliferation during pregnancy
and provide protection for the allogeneically-distinct con-
ceptus [17]. Ovine US decreases proliferation of lym-
phocytes stimulated with concanavalin A,
phytohemagglutinin (PHA), Candida albicans, and the
mixed lymphocyte reaction [18-22]. In addition, OvUS
decreases natural killer cell cytotoxic activity, abortion
induced by poly(I)poly(C) in mice [23] and the produc-
tion of antibody in sheep immunized with ovalbumin
[21]. The antiproliferative actions of OvUS are not limited
to lymphocytes. Ovine US decreases development of the
bovine embryos and proliferation of mouse lymphoma,
canine primary osteogenic sarcoma and human prostate
cancer cell lines [24,25].
The mechanism by which OvUS inhibits proliferation of
cells is unknown. The protein could block activation of
cell proliferation, inhibit the cell cycle at other points or
induce apoptosis or other forms of cell death. For the PC-
3 prostate cancer line, inhibition of cell proliferation by
OvUS might involve reduction in interleukin-8 (IL-8)
secretion because of the importance of autosecretion of
this cytokine for cell androgen-independent proliferation
[26]. The goal of the present study was to evaluate the
mechanism by which OvUS inhibits cell proliferation.
Using PC-3 cells as a model system, it was tested whether
inhibition of DNA synthesis involves cytotoxic action of
OvUS, induction of apoptosis or disruption of the IL-8
autocrine loop. It was also tested whether OvUS blocks
specific steps in the cell cycle for PC-3 cells and lym-
phocytes.
Results and Discussion
Proliferation of PC-3 cells
The antiproliferative effects of rOvUS on proliferation of
PC-3 cells were evaluated by two different assays. In the
first experiment, it was shown that rOvUS caused a con-
centration-dependent decrease in incorporation of
[3H]thymidine into DNA (P < 0.001) with the minimum
effective concentration being 8 μg/ml (Figure 1). The anti-
proliferative actions of OvUS using [3H]thymidine uptake
as the measure of proliferation has been demonstrated
previously for PC-3 cells and other cell types [18-
22,24,25]. To confirm this effect of rOvUS reflected an
inhibition in cell proliferation and not a disruption in
[3H]thymidine uptake by the cells, antiproliferative effects
were also evaluated by an assay in which the relative total
number of cells per well was estimated by the ATP content
per well. Treatment with rOvUS reduced ATP content per
well at all concentrations tested (50, 100 and 200 μg/ml)
(Figure 2). In contrast, the control serpin, ovalbumin, did
not cause effect in the ATP content per well. The finding
that rOvUS reduced ATP content per well confirms that
the effects of OvUS to reduce [3H]thymidine incorpora-
tion reflect a reduction in cell proliferation rather than
interference with [3H]thymidine transport into the cell.
Lactate dehydrogenase release
Possible cytotoxic effects of rOvUS on PC-3 cells were
evaluated by measurements of lactate dehydrogenase
release into culture medium (Figure 3). None of the con-
centrations of rOvUS or OVA tested caused an increase in
the percent of lysed cells during culture. Thus, rOvUS does
not inhibit proliferation through induction of cell death.
Inhibition of [3H]thymidine incorporation of PC-3 cells by  recombinant ovine uterine serpin (rOvUS) Figure 1
Inhibition of [3H]thymidine incorporation of PC-3 cells by 
recombinant ovine uterine serpin (rOvUS). The inset graph is 
provided to clarify the effects of rOvUS at lower concentra-
tions (≤ 8 μg/ml). Data represent least-squares means ± SEM. 
Values that differ from untreated cells are indicated by aster-
isks (***P < 0.001).
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DNA fragmentation (apoptosis)
The TUNEL procedure was used to test whether rOvUS
decreased cell proliferation by induction of DNA frag-
mentation characteristic of apoptosis and other forms of
cell death. Representative images of TUNEL labeled cells
are shown in Figure 4 and the average percent of cells that
were TUNEL positive is shown in Figure 5. Treatment of
PC-3 with either rOvUS or the control protein OVA did
not increase the percent of cells that were TUNEL positive
at either 24 or 48 h after treatment; the percentage of cells
that were TUNEL positive was low for all groups (< 5.7%).
The fact that rOvUS did not induce apoptosis makes the
action of this serpin distinct from that of two other serpins
that inhibit cell proliferation. Both maspin [6] and PEDF
[7] are proapoptotic serpins.
Interleukin-8 secretion
Interleukin-8 accumulation in the medium was measured
because of the autocrine effect of this chemokine on pros-
tate cell proliferation [26]. In addition, at least one class
of molecule that inhibits PC-3 cell proliferation, soy iso-
flavones, also reduces IL-8 secretion [27]. As shown in Fig-
ure 6, there was, however, no effect of rOvUS on
accumulation of IL-8 into conditioned cultured medium.
Thus, rOvUS does not block PC-3 cell proliferation
through inhibition of IL-8 secretion.
Cell cycle dynamics
Dynamics through the different phases of the cell cycle
were affected by the treatment of PC-3 cells with rOvUS.
Representative DNA histograms after treatment with vehi-
cle or 200 μg/ml rOvUS are shown in Figures 7A and 7B
while least-squares means ± SEM for for results at 12 and
24 h after treatment are shown in Figures 7C and 7D,
respectively. At 12 h after addition of treatments, rOvUS
decreased (P < 0.1 and P < 0.05 for 100 and 200 μg/ml of
rOvUS respectively) the percent of cells in S phase and
Representative photomicrographs of PC-3 cells labeled using  the TUNEL procedure after 48 h of culture with either 100  (A) or 200 μg/ml (B) of rOvUS or 200 μg/ml of the control  protein ovalbumin (C) Figure 4
Representative photomicrographs of PC-3 cells labeled using 
the TUNEL procedure after 48 h of culture with either 100 
(A) or 200 μg/ml (B) of rOvUS or 200 μg/ml of the control 
protein ovalbumin (C). Cells in panel D were treated with 
DNAse as a positive control.
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B
Inhibition of proliferation of PC-3 cells by recombinant ovine  uterine serpin (rOvUS) as determined by ATP content/well Figure 2
Inhibition of proliferation of PC-3 cells by recombinant ovine 
uterine serpin (rOvUS) as determined by ATP content/well. 
Ovalbumin (OVA) was used as a negative control. Data rep-
resent least-squares means ± SEM. Means that differ from 
untreated cells are indicated by symbols (†P < 0.1; **P < 
0.01; ***P < 0.001).
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Lack of cytotoxic effect of recombinant ovine uterine serpin  (rOvUS) on PC-3 cells was measured by the release of lac- tate dehydrogenase Figure 3
Lack of cytotoxic effect of recombinant ovine uterine serpin 
(rOvUS) on PC-3 cells was measured by the release of lac-
tate dehydrogenase. Ovalbumin (OVA) was used as a control 
protein. Data represent least-squares means ± SEM.
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increased (P < 0.01) the percent of cells in the G2/M phase
(Figure 6C). There was no effect of rOvUS on the percent
of cells in G0/G1. At 24 h after addition of treatment, 200
μg/ml rOvUS increased the percent of cells in G0/G1 (P <
0.001), decreased the percent of cells in S phase (P <
0.01), and did not affect the percent of cells in G2/M phase
(Figure 6D).
Control of the cell cycle dynamics by rOvUS was also eval-
uated in a second cell type – the peripheral blood lym-
phocyte. Representative DNA histograms for PHA-treated
lymphocytes are shown for control cells and cells treated
with 200 μg/ml rOvUS in Figures 8A and 8B, respectively
while least-squares means ± SEM are shown in Figures 8C
and 8D. At both 72 (Figure 8C) and 96 h (Figure 8D) after
addition of PHA, rOvUS increased (P < 0.001) the propor-
tion of lymphocytes in the G0/G1 phase and decreased (P
< 0.05) the proportion of cells in the S phase. In contrast,
there was no effect of the control protein (OVA) on the
distribution of cells in the cell cycle.
These results indicate that OvUS block cell proliferation
through cell cycle arrest in both PC-3 cells and lym-
phocytes. The differences in specific stages at which the
cell cycle was blocked between PC-3 cells and lym-
phocytes is likely to be caused by differences in activation
and regulation pathways for these two cell types. Unlike
PC-3 cells, lymphocytes are arrested at G0 until prolifera-
tion is induced by addition of PHA. Inhibition at points
in the cell cycle other than G0/G1 are less likely to be seen
since few cells progress to later stages of the cell cycle. In
addition, it is possible that genetic mutations in PC-3 cells
compromise some potential regulatory mechanisms. In
particular, unlike lymphocytes, PC-3 cells lack functional
p53 [28] which causes cell cycle arrest at G1/S by inducing
p21cip1 that inhibits cyclin dependent kinases [29,30].
The mechanism by which OvUS inhibits cell cycle dynam-
ics is not understood. One serpin has been identified
which can affect cell cycle regulatory proteins. This serpin,
myeloid and erythroid nuclear termination stage-specific
protein (MENT), is a nuclear protein that inhibits cell pro-
liferation through interactions with a nuclear protein with
papain-like cysteine proteinase activity [31]. Inhibition of
the proteinase prevents degradation of the cell cycle pro-
tein Rb although antiproliferative effects may depend
more on other actions of MENT to mediate euchromatin
condensation in an Rb-independent manner [31]. In any
case, OvUS, is apparently without proteinase inhibitory
activity and is an extracellular protein that is unlikely to
achieve a nuclear localization. The antipepsin activity of
Effect of recombinant ovine uterine serpin (rOvUS) on inter- leukin (IL) – 8 concentration in cell culture supernatants of  PC-3 cells Figure 6
Effect of recombinant ovine uterine serpin (rOvUS) on inter-
leukin (IL) – 8 concentration in cell culture supernatants of 
PC-3 cells. Ovalbumin (OVA) was used as control serpin. 
Data represent least-squares means ± SEM.
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Effect of recombinant ovine uterine serpin (rOvUS) on DNA  fragmentation (apoptosis) of PC-3 cells Figure 5
Effect of recombinant ovine uterine serpin (rOvUS) on DNA 
fragmentation (apoptosis) of PC-3 cells. Results show the 
percent of TUNEL positive cells at 24 (A) and 48 (B) h after 
addition of the treatments. Data represent least-squares 
means ± SEM. Ovalbumin (OVA, 200 μg/ml) was used as 
control protein.
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uterine serpin is probably not biologically significant.
OvUS is a very weak inhibitor of pepsin C (a 35 and 8 fold
molar excess of OvUS was required to inhibit pepsin A
and C [12]) C and the binding of OvUS to pepsin is elec-
trostatic [15]. Moreover, pepsin shows an acidic pH opti-
mum and is unlikely to be involved in cell proliferation
under the conditions utilized.
A major point in the cell cycle regulated by OvUS is tran-
sition from G0/G1 to S phase: rOvUS decreased the pro-
portion of cells in S phase in all experiments and
increased the proportion of cells in G0/G1 at 24 h after
treatment for PC-3 cells and at both times examined for
lymphocytes. Ovine uterine serpin can bind to cell mem-
branes [32] and, perhaps, OvUS inhibits proliferation by
activation of signal transduction systems that inhibit tran-
sition from G0/G1 to S phase or prevents pro-proliferative
molecules in culture medium from binding their recep-
tors. Experiments with Rp-8-Cl-cAMPS, a selective inhibi-
tor of cAMP-dependent type-I protein kinase A, indicated
that effects of OvUS on proliferation of PHA-stimulated
lymphocytes are not dependent on this kinase [24]. Stud-
ies to determine activation of other anti-proliferative sig-
nal transduction systems by OvUS are warranted.
Conclusion
The present study indicates that the mechanism by which
OvUS inhibits proliferation of PC-3 cells and lym-
phocytes involves cell cycle arrest and not, at least for PC-
3 cells, apoptosis, cytotoxicity or inhibition of IL-8 secre-
tion.
Cell cycle dynamics of PC-3 cells as affected by recombinant ovine uterine serpin (rOvUS) Figure 7
Cell cycle dynamics of PC-3 cells as affected by recombinant ovine uterine serpin (rOvUS). Controls included vehicle (control) 
and ovalbumin (OVA). Representative DNA histograms for analysis at 12 h after treatment with vehicle or 200 μg/ml rOvUS 
are shown in panels A and B, respectively. The least-squares means for results of three separate assays are shown in panels C 
and D for analysis at 12 h (C) and 24 h (D) after treatment. Bars with different superscripts differ († P < 0.10, others at P < 
0.05 or less).
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Methods
Materials
The human prostate cancer (PC-3) cell line was purchased
from ATCC (Rockville, MD), the FreeStyle™ 293 expres-
sion medium, Dulbecco's Modified Eagle Medium Nutri-
ent Mixture F-12 (DMEM-F12) and 0.25% Trypsin-EDTA
were obtained from Gibco-Invitrogen (Carlsbad, CA), the
RQ1 RNase-free DNase and the CellTiter-Glo® Lumines-
cent Cell Viability Assay kit were obtained from Promega,
(Madison, WI), the DHL™ Cell Cytotoxicity Assay kit was
from Anaspec (San Jose, CA) and the ELISA MAX™ Set
Deluxe kit for human IL-8 was obtained from BioLegend
(San Diego, CA). The in situ cell death detection kit [termi-
nal deoxynucleotidyl transferase-mediated dUTP nick end
labeling (TUNEL)] was purchased from Roche (Indianap-
olis, IN), the DNase-free RNase A was obtained from Qia-
gen (Valencia, CA), Precast Tris-HCl gradient Ready gels®
were from BioRad (Richmond, CA) and [3H]thymidine
(6.7 Ci/mmol) was from ICN (Irvine, CA). The Prolong
Antifade®  kit was purchased from Molecular Probes
(Eugene, OR), Geneticin was from Research products
international (Mount Prospect, IL), Centricon filter
devices were from Millipore Corporation (Bedford, TX),
niquel Sepharose chromatography medium (high per-
formance) was from Amersham Biosciences (Piscataway,
NJ), fetal bovine and horse serum from Atlanta Biologi-
cals (Norcross, GA). Other reagents were obtained from
either Fisher (Pittsburg, PA) or Sigma-Aldrich (St. Louis,
MO).
Cell cycle dynamics of lymphocytes as affected by recombinant ovine uterine serpin (rOvUS) Figure 8
Cell cycle dynamics of lymphocytes as affected by recombinant ovine uterine serpin (rOvUS). Controls included vehicle (con-
trol), phytohemagglutinin (PHA) and ovalbumin (OVA). Representative DNA histograms for analysis at 72 h after treatment 
with PHA or 200 μg/ml rOvUS are shown in panels A and B, respectively. The least-squares means for results of four separate 
assays are shown in panels C and D for analysis at 72 h (C) and 96 h (D) after treatment. Bars with different superscripts differ 
(P < 0.05 or less).
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Purification of rOvUS
The His-tagged rOvUS was purified from conditioned
medium of FreeStyle™ human embryonic kidney (HEK)-
293F cells (Gibco-Invitrogen, Carlsbad, CA) transfected
with a plasmid construct containing the gene for OvUS.
Details of the cell line are provided elsewhere [25]. Cells
were cultured continuously in selective medium [Free-
Style™ 293 expression medium containing 700 μg/ml of
Geneticin®] at 37°C in a humidified 8% (v/v) CO2 incuba-
tor according to the manufacturer's recommendations.
Conditioned medium containing rOvUS was diluted 1:1
(v/v) in binding buffer [20 mM sodium phosphate buffer,
35 mM imidazole, 0.3 M NaCl, pH 8.0] and loaded into a
nickel Sepharose column that was pre-equilibrated with
binding buffer. The His-tagged rOvUS was eluted with 20
mM phosphate buffer, 500 mM imidazole, 0.3 M NaCl,
pH 8.0, concentrated and buffer-exchanged into Dul-
becco's phosphate buffered saline (DPBS) using Centri-
con plus-20 concentration devices. Purity of the rOvUS
was assessed by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis using precast 4–15% polyacrylamide
Tris-HCl gradient gels. The protein concentration was
determined by Bradford assay [33] using bovine serum
albumin as standard.
For each experiment, rOvUS and the control protein,
OVA, were added to culture wells of PC-3 cells or lym-
phocytes dissolved in DPBS. The vehicle control included
addition of DPBS at the same volume as for rOvUS and
OVA. The actual volume of protein or vehicle added var-
ied between experiments but was generally 14–25 μl and
never more than 50 μl. Cultures were set up so that the
volume of DPBS was the same in all wells.
PC-3 cell culture
The PC-3 cell line was cultured continuously in Dul-
becco's Modified Eagle Medium Nutrient Mixture F-12
(DMEM-F12) supplemented with 10% (v/v) heat-inacti-
vated fetal bovine serum, 200 U/ml penicillin and 2 mg/
ml streptomycin at 37°C in a humidified 5% (v/v) CO2
incubator. For the IL-8 experiment only, the medium was
modified to reduce the fetal bovine serum concentration
to 4% (v/v). For all the experiments, cells were cultured in
75 cm2 flasks until they reached 50–70% of confluence.
Cells were then trypsinized, centrifuged at 110 × g for 5
min and resuspended in fresh complete medium. Cell via-
bility was assessed by trypan blue exclusion and cell con-
centration was adjusted according to the requirements of
each experiment.
[3H]Thymidine incorporation by PC-3 cells
PC-3 cells (100 μl) were plated overnight at a final con-
centration of 1 × 105 cell/ml in a 96-well plate. Afterwards,
various concentrations of rOvUS (0, 0.5, 1, 2, 4, 8, 16, 32,
64, 125 and 250 μg/ml) or vehicle were added to each
well in a total volume (including additional culture
medium) of 200 μl. After 48 h of culture, 0.1 μCi [3H]thy-
midine in 10 μl of culture medium were added. Cells were
harvested 24 h after [3H]thymidine addition onto fiber-
glass filters using a cell harvester (Brandel, Gaithersburg,
MD). Filters were counted for radioactivity using scintilla-
tion spectrometry (Beckman Coulter Inc., Fullerton, CA).
Each concentration of protein was tested in triplicate and
the experiment was performed in six different replicates
using a different batch of rOvUS for each replicate.
Cell proliferation based on ATP content
Aliquots of 50 μl of PC-3 cells (1 × 105 cells/ml) were cul-
tured for 24 h in a dark wall-clear bottom 96 well plate.
Then, treatments consisting of vehicle (DPBS) or three dif-
ferent concentrations (50, 100 and 200 μg/ml) of rOvUS
or a control protein (OVA) and culture medium added to
bring the final volume to 100 μl. Additional control wells
without cells were prepared to determine background. At
48 h after addition of treatments, ATP content per well
was determined using the CellTiter-Glo® Luminescent Cell
Viability Assay kit according to the manufacturer's instruc-
tions. Briefly, 100 μl of the CellTiter-Glo® reagent were
added to each well, contents of the plate were mixed on a
shaker for 2 min and then incubated at room temperature
for 10 min. Chemiluminescence was quantified using a
multi-detection microplate reader (FLX-800, BioTek,
Winooski, VT). All treatments were performed in tripli-
cates and the assay was performed on three different occa-
sions using a different batch of rOvUS for each replicate.
Cytotoxicity assay
The assay was based on the release of lactate dehydroge-
nase into culture medium following loss of cell mem-
brane integrity accompanying cell death [34]. Procedures
for cell culture and treatments were similar to those
described for the ATP assay. At 48 h after addition of the
treatments, release of lactate dehydrogenase into the
medium was determined using the DHL™ Cell Cytotoxic-
ity Assay kit following the vendor's instructions. Briefly,
the plate was equilibrated at room temperature for 20 min
before adding 10 μl of lysis solution or DPBS. To facilitate
cell lysing, the plate was placed on a shaker for 2 min. A
total of 50 μl lactate dehydrogenase assay solution was
then added to each well. After 10 min at room tempera-
ture, the reaction was stopped using 20 μl of the stop solu-
tion and the fluorescence intensity was measured using a
multi-detection microplate reader (FLX-800) with excita-
tion and emission wavelengths of 530–560 nm and 590
nm, respectively. Percent cytotoxicity was calculated by
dividing 100 × fluorescence from the unlysed cells by flu-
orescence of the lysed cells. For each assay, each treatment
was performed in six wells. The assay was replicated five
different times using a different batch of rOvUS for each
replicate.BMC Cell Biology 2008, 9:5 http://www.biomedcentral.com/1471-2121/9/5
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TUNEL labeling
An aliquot of 100 μl of PC-3 cells were cultured overnight
in chamber slides at a final concentration of 1 × 104 cells/
ml. Then, treatments consisting of vehicle (DPBS), 50,
100 or 200 μg/ml rOvUS, or 200 μg/ml OVA were added
and additional culture medium added to produce a final
volume of 300 μl. After 24 and 48 h in culture with treat-
ments, cells were washed with PBS/PVP [100 mM sodium
phosphate pH 7.4, 0.9% (w/v) NaCl, 1 mg/ml polyvinyl
pyrrolidone] and fixed with 4% (w/v) paraformaldehyde
for 1 h at room temperature. Cells then were washed in
PBS/PVP and stored at 4°C for the TUNEL (terminal deox-
ynucleotidyl transferase and fluorescein isothiocyanate-
conjugated dUTP nick end labeling) procedure.
For TUNEL labeling, fixed cells were incubated for 1 h at
room temperature with permeabilization solution [PBS,
pH 7.4, 0.1 (v/v) Triton X-100, 0.1% (w/v) sodium cit-
rate). After washing with PBS/PVP, slides were incubated
with 50 μl of TUNEL reaction mixture containing terminal
deoxynucleotidyl transferase and fluorescein isothiocy-
anate-conjugated dUTP, for 1 hour at 37°C. Positive con-
trols were preincubated with RQ1 RNase-free DNase (50
U/ml) and negative controls were incubated without
transferase. Slides were washed with PBS/PVP, incubated
for 1 h with 50 μg/ml of RNase A and then for 30 min with
propidium iodide (2.5 μg/ml) at room temperature.
Slides were washed with PBS/PVP and Prolong Antifade®
was used to mount coverslips. Samples were observed
using a Zeiss Axioplan 2 fluorescence microscope with
dual filter (Carl Zeiss, Inc., Göttingen, Germany). Percent
of cells with DNA fragmentation was determined by
counting the total number of nuclei and total number of
TUNEL-labeled nuclei at 10 different sites on the slide.
The experiment was performed using three different
batches of rOvUS.
Secretion of IL-8
PC-3 cells (100 μl) were cultured in wells of a 96-well
plate overnight at a final concentration of 1 × 105 cells/ml.
Treatments were then added including vehicle (DPBS,
similar volume as for rOvUS and OVA treatments), and
three different concentrations of rOvUS and OVA (50,
100 and 200 μg/ml). The volume of each well was
brought to 200 μl with culture medium. At 48 h after addi-
tion of treatments, cell culture supernatants were col-
lected, centrifuged and stored at -20°C until ELISA for IL-
8. Treatments were performed in triplicate for each assay;
the experiment was repeated on three different occasions
using three different batches of the recombinant protein.
For the measurement of IL-8, the ELISA MAX™ Set Deluxe
kit for human IL-8 was used according to the manufac-
turer's instructions using 100 μl of conditioned medium.
Cell cycle analysis
PC-3 cells (100 μl) were cultured in 4 well plates at a final
concentration of 4 × 105 cells/ml. After 24 h, treatments
consisting of vehicle, 100 and 200 μg/ml rOvUS, and 200
μg/ml OVA were added with additional culture medium
for a total volume of 400 μl. At 12 and 24 h after addition
of treatments, cells were collected by trypsinization and
washed with DPBS. Cells were fixed overnight in 70% (v/
v) ethanol at 4°C, washed with DPBS and resuspended
with 500 μl of staining solution [DPBS pH 7.4, 0.1% (v/
v) Triton X-100, 0.05 mg/ml DNase-free RNase A, 50 μg/
ml propidium iodide]. Cells were then analyzed by flow
cytometry using a FACSort flow cytometer (Becton Dick-
inson, Franklin Lakes, NJ) and the red fluorescence of sin-
gle events was recorded at wavelengths of 488 nm
(excitation) and 600 nm (emission). Data were gated
using pulse width and pulse area to exclude doublets, and
the percent of cells present in each phase of the cell cycle
was calculated using ModFITLT V3.1 software (Verity Soft-
ware, Topsham, ME). The experiment was performed on
three occasions with five different batches of rOvUS.
For the sheep lymphocyte experiment, mononuclear cells
were purified by density gradient centrifugation from the
buffy coat of heparinized peripheral blood collected by
jugular venipuncture from non pregnant Rambouillet
ewes [35]. After removing red blood cells by incubation
with red cell lysis buffer (0.01 M Tris-HCl pH 7.5 contain-
ing 8.3 g/L of ammonium chloride), cell viability was
assessed by trypan blue exclusion, and concentration
adjusted to 4 × 106 cells/ml. Cells were then suspended in
a culture medium consisting of Tissue Culture Medium-
199 containing 5% (v/v) horse serum, 200 U/ml penicil-
lin, 0.2 mg/ml streptomycin, 2 mM glutamine and 10-5 M
β-mercaptoethanol and aliquots of 100 μl cells cultured in
4 well plates in the presence or absence of 4 μg/ml PHA
and with treatments of DPBS vehicle, 200 μg/ml rOvUS,
and 200 μg/ml OVA. Total culture volume was 400 μl.
After 72 and 96 h in culture at 37°C in a humidified 5%
(v/v) CO2  incubator, lymphocytes were collected and
washed with DPBS. Thereafter, lymphocytes were fixed
and treated as described above. The experiment was per-
formed separately for lymphocytes from four different
sheep. Three different batches of rOvUS were tested for
each sheep.
Statistical analysis
Data were analyzed by least-squares means analysis of var-
iance using the General Linear Models Procedures of SAS
(SAS System for Windows, Version 9.0; SAS Institute,
Cary, NC, USA). Error terms were determined based on
calculation of expected mean squares with replicate con-
sidered random and other main effects considered fixed.
For the cytotoxicity and IL-8 data, orthogonal polynomial
contrasts were used to determine the linear and quadraticBMC Cell Biology 2008, 9:5 http://www.biomedcentral.com/1471-2121/9/5
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effects of rOvUS and OVA. In other analysis, the pdiff
mean separation test of SAS was used to distinguish the
difference of various levels of a treatment.
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